{
    "title": "109_s1903",
    "content": "The Act titled \"Generic Prescription Drug Fairness Act of 2005\" aims to regulate authorized generic drugs and other drugs approved under Section 505(c) of the Federal Food, Drug, and Cosmetic Act. The Act \"Generic Prescription Drug Fairness Act of 2005\" regulates authorized generic drugs and other drugs approved under Section 505(c) of the Federal Food, Drug, and Cosmetic Act by amending Section 1927(b)(3)(A) to include reporting on average manufacturer prices for covered outpatient drugs. The Generic Prescription Drug Fairness Act of 2005 regulates authorized generic drugs and other drugs approved under Section 505(c) of the Federal Food, Drug, and Cosmetic Act by requiring reporting on manufacturer's best prices for rebate agreements. The Generic Prescription Drug Fairness Act of 2005 regulates authorized generic drugs and other drugs approved under Section 505(c) of the Federal Food, Drug, and Cosmetic Act by requiring reporting on manufacturer's best prices for rebate agreements. Amendments to Section 1927 of the Act include specifying the inclusion of authorized generic drugs and other approved drugs under rebate agreements. The Generic Prescription Drug Fairness Act of 2005 regulates authorized generic drugs and other drugs approved under Section 505(c) of the Federal Food, Drug, and Cosmetic Act by requiring reporting on manufacturer's best prices for rebate agreements. Amendments to Section 1927 of the Act include specifying the inclusion of authorized generic drugs and other approved drugs under rebate agreements, with additional requirements for manufacturers allowing authorized generic drugs to be sold under new drug applications. The Generic Prescription Drug Fairness Act of 2005 regulates reporting on manufacturer's best prices for authorized generic drugs and other approved drugs under rebate agreements. Amendments to Section 1927 specify requirements for manufacturers regarding the lowest price available to various entities within the United States. The Generic Prescription Drug Fairness Act of 2005 regulates reporting on manufacturer's best prices for authorized generic drugs and other approved drugs under rebate agreements. Amendments to Section 1927 specify requirements for manufacturers regarding the lowest price available to various entities within the United States. The term 'authorized generic drug' includes the average price paid for such drugs by wholesalers for drugs distributed to the retail pharmacy class of trade, after deducting customary prompt pay discounts. The Generic Prescription Drug Fairness Act of 2005 defines a generic drug as a listed drug approved under section 505(c) of the Federal Food, Drug, and Cosmetic Act, marketed under different labeling or packaging. The amendments take effect on October 1, 2005. SEC. 3. APPLICATION OF BASIC REBATE FOR SINGLE SOURCE AND INNOVATOR MULTIPLE SOURCE DRUGS. The amendment to Section 1927(c)(1) of the Social Security Act expands the types of drugs subject to rebate requirements to include authorized generic drugs and other drugs approved under a new drug application. The effective date of these amendments is the date of enactment of the Act. The rebate agreements under this Act will take effect on the date of enactment and apply to agreements entered into or renewed after that date."
}